(Bloomberg) — Eli Lilly & Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by the blockbuster weight-loss drug Zepbound.
Most Read from Bloomberg
The company also raised its quarterly dividend 15%, according to a statement Monday. The shares rose as much as 1.3% in late trading after the US markets closed.
The share repurchases may be made from time to time at management’s discretion, Lilly said.
Most Read from Bloomberg Businessweek
©2024 Bloomberg L.P.
Source: finance.yahoo.com
Related posts:
SEC Sues Binance. What It Means for Bitcoin and Coinbase.
Elizabeth Holmes Sentencing: A History of the WSJ Theranos Investigation
Invest $50k In This Stock To Become A Dividend Millionaire In 10 Years
Why I Keep Loading Up on These High-Yielding, Renewable-Energy Dividend Stocks
If You'd Invested $200 in Shiba Inu in 2020, This Is How Much You'd Have Now